Podcasts about carien

Carien Rennie is the owner of a local Kelowna Real Estate business called Luxury Living BC. She is also a contributing author in our first book; Let's Not Sugarcoat It: Real, Raw, and Honest Conversations Without the BS. In this episode we 'get into it' with Carien about: -clearing past patterns-letting go of what no longer serves-stepping into a new career -owning her path-the role faith and god have played in her journey -Kelowna real estate and more! Follow Carien on IG or visit her website. We still have a few spots left in our upcoming Book and Speaker Series. Apply today.

(01:25) Frans Willem de Haas over Pierre Audi (19:14) Abdelkader Benali over migratiemuseum Fenix (52:53) Wat blijft lijn: Fadime Demir over haar vader Davut Demir (56:53) Carien Kremer over Annie Vriezen (01:07:16) Grote Geesten: Emmie Kollau maakte deze podcast over het leven van Albert Camus (01:47:23) De Zin van de Dag: Stephanie Struijk met een zin van Annie M.G. Schmidt (01:51:33) Muziek van Bob Marley

In haar nabije omgeving heeft Nanette te maken met personen die na een heftige traumatische ervaring als mishandeling of incest, zelf dader van dezelfde daden worden. Ze wil graag begrijpen hoe dat werkt. En hoe kunnen deze personen het beste geholpen worden? Psychotherapeut en auteur Carien Karsten, ondermeer bekend van de bestseller Hoe swipe je een trauma weg, geeft onder begeleiding van presentator Rachel van de Pol inzicht in deze complexe en veelgehoorde vraag. Carien is een veelgevraagd en ervaren specialist op het gebied van trauma, burn-out en verslaving. Volg de podcast en mis geen aflevering! Lees of luister de boekentip van deze week: Zachtop lachen, Malou HolshuijsenAlleen en duizend mensen, Malou Holshuijsen De Zelfhulpvraag Heb je zelf een vraag? Stuur je brief naar zelfhulpvraag@vbk-audiolab.nl En volg ons op Instagram @dezelfhulpvraag voor nog meer concrete zelfhulptips, mooie videofragmenten en updates. Heb je een vriendin/zus/moeder/vriend/neef/vader die wat aan deze aflevering zou kunnen hebben? Stuur hem dan door! En wil je geen aflevering missen? Volg dan de show! See omnystudio.com/listener for privacy information.

Erik (39) worstelt zijn hele leven al met zijn emotioneel onvolwassen moeder. Na een bezoek moet hij soms een week hiervan bijkomen. Hij vraagt zich of hoe hij het contact met zijn moeder kan onderhouden zonder er zelf zoveel last van te ondervinden. Psychotherapeut en auteur Carien Karsten, ondermeer bekend van de bestseller Uit je burn-out, geeft onder begeleiding van presentator Rachel van de Pol perspectief en advies. Carien is een veelgevraagd en ervaren specialist op het gebied van trauma, burn-out en verslaving. Volg de podcast en mis geen aflevering! Lees of luister de boekentip van deze week: De emotioneel afwezige moeder, Jasmin Lee Cori De Zelfhulpvraag Heb je zelf een vraag? Stuur je brief naar zelfhulpvraag@vbk-audiolab.nl En volg ons op Instagram @dezelfhulpvraag voor nog meer concrete zelfhulptips, mooie videofragmenten en updates. Heb je een vriendin/zus/moeder/vriend/neef/vader die wat aan deze aflevering zou kunnen hebben? Stuur hem dan door! En wil je geen aflevering missen? Volg dan de show! See omnystudio.com/listener for privacy information.

Stefan, Carien en ek gesels oor over word en verjaar

Ellen worstelt met haar rol bij de familieproblemen van haar vriend. Sinds twee jaar wil zijn jongste dochter geen contact meer met hem. Ze ziet dat iedereen er onder lijdt, maar ook dat de situatie niet verbetert door koppigheid en oude pijn aan beide kanten. Haar vraag is: hoe ga ik hier als buitenstaander mee om? Psychotherapeut en auteur Carien Karsten, ondermeer bekend van de bestseller Uit je burn-out: een 30 dagen programma, geeft onder begeleiding van presentator Rachel van de Pol perspectief en advies. Carien is een veelgevraagd en ervaren specialist op het gebied van trauma, burn-out en verslaving. Volg de podcast en mis geen aflevering! Genoemd in de aflevering:

Sinds een half jaar zit Mart (39) thuis door een burn-out in het onderwijs. Het gaat wat beter, maar hij heeft nog steeds last van slecht slapen, nachtmerries, flashbacks en gepieker. Dit staat zijn herstel in de weg. Zijn vraag is: hoe komt hij hier vanaf? Psychotherapeut en auteur Carien Karsten, ondermeer bekend van de bestseller Uit je burn-out: een 30 dagen programma, geeft onder begeleiding van presentator Rachel van de Pol perspectief en advies. Carien is een veelgevraagd en ervaren specialist op het gebied van trauma, burn-out en verslaving. Genoemd in de aflevering:

Carien en ek gesels bordspeletjies

Ons gesels oor ons eerste skooldae - Carien ek en Stefan

Stefan, Carien en ek gesels oor die verhoog en genot

“Als het gaat om kritische participatie in beroepen en samenleving; dan vraagt dat ook om kritische participatie in de school. Dan vraagt dat, dat we van leerlingen verwachten dat ze leren invloed uit te oefenen. Het vraagt dat we het instrumentele karakter van participatie overstijgen. Het vraagt dat we leerlingen uitnodigen om onze eigen regels […] kritisch te bevragen en ter discussie te stellen”. Aan het woord is Carien Verhoeff, partner bij Vanderkruis Executive Search en tot augustus jl. associate lector aan de De Haagse Hogeschool, over het bevorderen van leerling-participatie in de school. In deze aflevering van VO-praat legt Carien de beginselen uit van leerling-participatie 2.0. Meer weten over deze reeks? Kijk op www.vo-academie.nl/vo-praat

Leaders in Conversation with Anni Townend is the podcast in which I talk to leaders about their own life and leadership stories, to encourage you to reflect on your values, beliefs, passion and purpose, and inspire you to be even more confident and courageous in your leadership.About this episode: Today's guest is Carien Borst, Artist and Leadership Coach. In this episode we are talking about Creativity and Reflection in Leadership - how every job is a creative act, and how we all have a part to play in creating a workplace and environment in which there is harmony, diversity and contrast.Carien offers valuable insights into:How as human beings we are all creativeHow through being creative it can be an endless source of life energyKnowing and being yourself - how being authentic and vulnerable gives others permission to be authentic and vulnerableCreativity and how it's related to leadership Carien's Three Key Encouragements to Leaders:Know yourself, and be yourself - We serve the world by showing ourselves who we are! Explore, experiment, play and be creative - Let go of the outcome and experience joy! Remember to play and take time to simply enjoy creative activities. We create all day - By choosing our words and by our reaction towards others. Connect, follow and find out more about Carien:LinkedIn: Carien (Mooibroek) Borst Website: www.carienborst.nl Instagram: @carien_borst_artTo listen to other Leaders in Conversation with me Anni Townend: Email me on anni@annitownend.com Visit my website www.annitownend.com  Follow me on LinkedInAbout Carien Borst:Carien was born and raised in the Netherlands. She studied Art Therapy and Human Development. Carien worked for 15 years in mental healthcare, and for about 10 years in different leadership roles. She started as a team leader and the last years as a manager of the eleven sheltered living houses for people who suffered from all sorts of psychiatric diseases.Around 7 years ago Carien started to realise she was missing creativity in her life. Due to a busy job, two young children and simply not prioritising what she needed. After a weekend spent in a monastery, filled with silence and creativity she decided to change things in her life. She woke up early every day to create in silence. Writing, creating an art journal, sitting still and taking time to think and feel. She chose to follow art courses and slowly new ideas developed. How could she bring this creativity into her leadership role?She found the courage to bring three pillars together in her own business: creativity, leadership and reflection. Based on her experience as a leader in mental healthcare but also through her journey in opening up again for the power of creating and growing in being a painter and artist. 

Carien en ek kuier

Van seereis, Namibie, die wind en meer met my, Stefan en Carien

Carien is op Stroud

Welcome to another exciting episode of the "Cowgirls with Cameras" podcast! On this episode, your favorite hosts, Kim, Cara, and Phyllis, saddle up for an insightful conversation with the renowned Carien Schippers of the Equine Photographers Network (EPNet).Dive deep with us as we explore the origins of EPNet, understanding why Carien felt the need to create this unique platform over 23 years ago. We'll discuss the significant changes and evolutions within the network and where it's headed in the future.In a field often marked by solitary pursuits, we'll discuss the shift from working in isolation to embracing collaboration. Carien shares her insights on the joy and empowerment stemming from in-person events, highlighting how these gatherings can spark creativity and drive in equine photography.No discussion with Carien would be complete without touching upon the power of networking and community. Learn how these elements are not just buzzwords but the backbone of thriving in the equine photography arena.Lastly, we'll venture into the future, discussing the changes in technology and their impact on photography. We'll ponder over the future markets for young photographers and the challenges and opportunities presented by tech advancements and AI.So, gsettle in with your favorite beverage, and join us for this enlightening episode that promises to inspire, inform, and maybe even make you chuckle a bit. Whether you're a seasoned pro or a budding equine photographer, there's something in this episode for everyone! Don't forget to subscribe and leave us a review!

Dr. Shannon Westin and her guest, Dr. Nanda Horeweg and Dr. Carien Creutzberg, discuss the paper "Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer" recently published in the JCO. TRANSCRIPT  The guest on this podcast episode has no disclosures to declare. Shannon Westin: Hello everyone, and welcome to another episode of JCO After Hours, the podcast where we get in-depth on manuscripts published in the Journal of Clinical Oncology. I'm your host Shannon Westin, Social Media Editor for the JCO and GYN Oncologist by trade. And I'm so excited about today's topic because it is a GYN Oncologist dream. Before I start, please note that none of the authors have any conflict of interest. We are going to be discussing molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial cancer. And this was published in the JCO on September 20th, 2023. And we're going to be speaking to two of the lead authors. First is Nanda Horeweg. She's a senior researcher in the Department of Radiation Oncology at the Leiden University Medical Center in the Netherlands. Welcome. Nanda Horeweg: Thank you. Happy to be here. Shannon Westin: And Dr. Carien Creutzberg. She's professor at the Department of Radiation Oncology at the Leiden Medical Center as well. Carien Creutzberg: Thank you. Shannon Westin: So, let's get into it. And I want to really level set because we have a mixed audience here. So, why don't you start by speaking about the incidents and mortality of endometrial cancer? Nanda Horeweg: Yes, of course. Endometrial cancer is the sixth most common cancer in women with around 400,000 new diagnoses made globally each year. And a woman's lifetime risk to get endometrial cancer is around 3%, and the median age, the diagnosis is 61 years. Most of the women who are diagnosed with endometrial cancer are diagnosed at an early stage, around two thirds, and they have an excellent prognosis. Actually, the five-year survival rates are around 92%. For stage 2 disease, this is actually already going down a bit to 74%. Therefore, stage 3 disease is only 48%. Women that are diagnosed with advanced disease have only a five-year survival, 15%. Shannon Westin: So, given that we know the majority of endometrial cancers are diagnosed at this early stage, prior to your evaluation, what was known about the optimal way to treat this early-stage patient population? Carien Creutzberg: Well, of course, the PORTEC trials were done … were started PORTEC-1 in the 19th of the last century, and PORTEC-2 in 2002. So, at that time, there were still many, many women treated adjuvantly with external beam radiation therapy. And we just developed risk factors to decide on their risk and the incidents for radiotherapy. And in PORTEC-2, because in PORTEC-1 we had seen that most of the recurrences in these early stage cancers were in the vaginal fold, we compared local vaginal brachytherapy only three sessions within full course of pelvic radiotherapy and showed that it had similar pelvic control and survival. Of course, this study, which Nanda conducted, was a long-term analysis with many new factors known from the translational research in the tissue samples of these patients who participate in PORTEC-1 and 2. And in the meantime, we've developed much more knowledge on the molecular factors and other important factors such as LVSI, which tell us much more about the individual prognosis to patients. So, the treatment has been developing greatly in the past 20 years. Shannon Westin: Yeah, and I think this is a great case of less is more, right? We were doing so much for so many people that really didn't need it. And so, really tailoring who needs less treatment, who doesn't need any treatment, and then also, conversely, who may need more treatment that would be missed by the traditional risk factors that you're speaking of. So, I think that brings us right into my next question, which is just bringing the audience up to date on the cancer genome atlas and how that's changed the way we classify endometrial cancer. Nanda Horeweg: Yes, I think the molecular classification of the TCGA has shaped the way we think about endometrial cancer, and has huge impact on decisions on adjuvant treatments in the years to come. The TCGA performed an extensive characterization of the endometrial cancers and found that in fact, this disease exists of four different groups. And the first of the groups I'd like to discuss is the ultra-mutated group, which is characterized by POLE mutations. And this group is shown to have an excellent prognosis in many independent studies. A second group that also has a high mutational burden is characterized by microsatellite instability, and mismatch repair deficiency and has shown to have an intermediate prognosis. Then there's another group that has a low mutational burden with high copy number alterations and frequent TP53 mutations, and these have a poor prognosis. And then lastly, there's a group that does not have any of the classifying features and is often called non-specific molecular profile or TP53 wild type. And this group also has an intermediate prognosis. And then finally, there's a small group of cancers that has more than one of these classifying features, the so-called multiple classifiers. And the WHO 2020 has developed an algorithm which can be used to classify them into the four groups. And that's first on the POLE status. And for the POLE wild type tumors, they are assigned according to mismatch repair deficiency status. And for those that are mismatch repair proficient than POLE wild type, they are classified according to the TP53 status into NSMP or p53 abnormal. Carien Creutzberg: Yeah, that is because of in the ultra-mutated and hyper mutated groups, many of the other mutations are secondary mutations in the context of the ultra-mutated stage, and they behave like the first molecular group. Shannon Westin: Yeah. So, that POLE mutation is going to trump anything else, and it's so important. And I will just say as a sidebar, it's been challenging with the price of next gen sequencing sometimes to get that for everyone. So, sometimes for us when we see a p53 mutation, we actually go back and do the full next gen sequencing to make sure that we're not going to act on that core prognostic feature when it really is in the setting of that more simplistic or that more positive prognostic place. So, this is great, we already kind of highlighted a little bit PORTEC-1 and 2, but if you don't mind, I would love to get the audience a little bit more information just maybe about the populations that were included as we were figuring out how aggressive to be with radiation just to remind people of that, or to teach them that if they haven't gotten a chance to look at those studies. Carien Creutzberg: Yeah, that's important to know because PORTEC-1 was still in the era that we also treated intermediate risk stage 1 endometrial cancer patients. So, deep invasion with grade 1 and 2 or superficial invasion with grade 2 and 3. That's what we defined at that point. Then we compared external beam radiation or no further treatment, showing no survival difference, but a higher risk of recurrence with higher risk being older age over 60, grade 3 for deep myometrial invasion. And we kept those high intermediate risk factors as also similarly found by GOG-99 at the time to do PORTEC-2. So, at the time, about 50% of patients did not have an indication for adjuvant therapy anymore, and with a high intermediate risk population for PORTEC-2, we compare external beam or vaginal brachytherapy and found the benefit of vaginal brachytherapy. A simple outpatient treatment, very short with almost no side effects ensuring local control. And nowadays, using the molecular classification of PORTEC-4a, we've compared achieving treatment with or without use of the molecular factors to designated treatment. So, the standard arm is vaginal brachytherapy and investigational arm is first, a molecular risk profile. And then we give no radiotherapy for those with a favorable profile, then a brachytherapy for the intermediate ones, and for the small group is either extensive LVSI or TP53 mutation or L1 chem overexpression external beam. And we hope to show that less overtreatment and less undertreatment will benefit these patients. Shannon Westin: Yeah, I'm very much looking forward to the results of PORTEC-4a. But let's circle back and talk a little bit about your amazing work here. So, how did you leverage those patient populations from PORTEC-1 and 2 for the current study? Nanda Horeweg: Yes. Well, the PORTEC-1 and 2 study provided a unique opportunity to look into differential treatment effects for radiotherapy. And that is because these are randomized trials, so the groups are comparable, and we have long-term follow-up data that's of very high-quality. In addition, as Carien said earlier, she had the vision already back in the nineties to directly ask the patients permission for the collection of the tissue. So, we have a broader complete biobank for both of these trials, which is quite unique. And our colleagues, Professor Smit and also Charlene Goseff from the pathology department, they have done extensive work on molecular classification, and have molecularly characterized all these cases. So, this allowed us to include 880 patients in this study, which is the largest so far. And besides like the very good starting point that we have of PORTEC-1 and 2 is that we also chose a design that was optimized to conduct like real causes, the causal effects of the molecular class on radiotherapy response. So, we tried to preserve this randomization effect, the exchangeability of the groups as much by working with the intention to treat population and not excluding any patients, except for when they did not have the molecular classification assessed. And also, we looked at areas in the body that were irradiated in one group and not in the other one to really observe the effect of radiotherapy as much as possible. So, looking to the entire pelvis, so local and regional recurrences in PORTEC-1 and looking at pelvic recurrences in PORTEC-2. Shannon Westin So, how were the intervention outcomes in this study different based on the TCGA classifiers? Nanda Horeweg: Before I tell you the results of biomolecular group, I think it's good to have the starting point of the analysis here. So, the no hypothesis of my study was to see whether there was any difference, and no hypothesis is that there's no difference. So, if we find a significant effect, then we can actually say that we found something. And if we start with the POLE group, we did not find any significant difference between the groups allocated to radiotherapy or not. But we did see not a single recurrence in any of the patients that we included from both of these trials. So, technically speaking, we did not find a predictive effect of the molecular classifier, but a prognostic effect. There's no one's having recurrence, so we can deduct from that, that radiotherapy is probably over treatment. Then for the MMRd group, we did observe some recurrences, but these were not significantly different between these three groups. So, based on this study, we cannot draw conclusions on which type of radiotherapy we should give to the patients or whether we should give radiotherapy at all. This was very different for the p53 group. There, the patients had lots of recurrences, unfortunately, as we expected, but we saw a big difference in outcome compared between no radiotherapy at all if it's vaginal brachytherapy where we still had lots of recurrences, and EBRT where we hardly saw any recurrences in the pelvis. And that difference was significantly different. So, that's an indication that these patients need more than just vaginal brachytherapy, even though it's only stage 1 endometrioid endometrial cancer. And then in the last group, the NSMPs, we saw even a different pattern where patients who had had external beam radiotherapy or vaginal brachytherapy, both had an excellent local regional control, and the ones that did not receive any treatments had more recurrences. And this was also very significant. So, there, you would conclude that both therapies are appropriate, but of course, the toxicity profile for vaginal brachytherapy is much more favorable than that of EBRT. Shannon Westin: We really are getting kind of consistent data around p53 needing more treatment. And I think the natural question that comes here, for me at least, and I know we can't answer it with the work, is would chemo be — would that be that extra treatment, when we saw with PORTEC-3 that the group needed the chemotherapy the most. So, I think we'll have to continue to work through that and determine is any more treatment what we need or specific treatments really the best. So, this is so intriguing and it's nice that it's consistent, that we're seeing that across these different studies that really kind of lends strength and validity, I think to what we're finding. So, one of the actions that we're kind of moving towards and that you advocate certainly in your paper is omitting therapy for patients with POLE mutations. Are there any ongoing studies around that that will help us confirm that this is safe for our patients? Nanda Horeweg: Yeah, that's a very good point. I think the evidence is strong enough now to conduct prospective trials. And of course, these are ongoing, the PORTEC-4a trial was already briefly mentioned there. The patients with poor mutations will be randomized between observation and vaginal brachytherapy. So, that will give us a good indication whether in this high intermediate risk early-stage group omission is safe. And in addition to that, we are also conducting with the RAINBO Consortium, the RAINBO-BLUE trial, wherein patients also with high-risk features, so non-endometrioid isotypes, LVSI and higher stages are included. And also in those patients, we investigate whether the de-escalation of treatment is safe. So, we're definitely looking forward to those results to be able to transfer this knowledge to clinical practice later on. Carien Creutzberg: And maybe it's nice to add that RAINBO BLUE is connected to the Canadian Taper trial. Taper being a general de-escalation trial where the POLE patients in that trial are also feeding into the RAINBO-BLUE. And I know that in North America, many centers will participate in the Taper trial. Shannon Westin: Yes, I think everyone is very excited and I think it'll be nice to have these two very strong studies that will help us really confirm that that is 100% a test that needs to be done, cost are not — and that will help avoid overtreatment of patients. So, in line of that, have you all experienced any challenges with implementing molecular testing across patients with endometrial cancer? Any thoughts on how we could potentially simplify? You talked about the rational promise algorithm, which I think is excellent, but I'm just curious to hear your thoughts on this. Nanda Horeweg: The implementation of the molecular classification can be challenging. We have to be honest about that. And usually, it's the assessment of the POLE status that's causing the problems because that's usually done with NGS, which is quite expensive. It requires a lot of knowledge in the laboratory and it's also a bit time-consuming. So, that is the bottleneck for most laboratories and for most settings. But this is already changing in a couple of places, like in the UK and the Netherlands, it's being reimbursed by healthcare insurances, and also, in many tertiary care centers in other countries, they're already systematically performing this test. But of course, there will always be places where this is not feasible. And luckily, there are also cheaper alternatives coming up and are already available at the moment. So, one of them is, for example, standard sequencing, which is not so expensive, but a bit labor intensive. Some colleagues we work with from India have implemented that in their clinical practice and are perfectly able to molecularly classify the endometrial cancers in daily practice. Another alternative is a test that we've developed in Leiden that's called the QPOLE test, which is based on qPCR, so that's a technology which we use for our COVID test around the world, so that can be done almost anywhere. And with that, you have a very high accuracy to detect unknown pathogenic variants. And this is also published in JCO Global Oncology, and can be implemented in any center after a local validation step. And even like more companies nowadays are realizing that this is important. So, I think commercial tests are already becoming available and very more on the market soon. So, I am really hoping that it'll be more available to endometrial cancer patients. Carien Creutzberg: And they'll offer them at a very low cost and also a rapid turnaround because NGS can take like 10 days. But realizing on a more national level, if you have found one patient with a POLE mutation, the omission of cycles of chemotherapy with all of the patient care around in the hospital is worth much more than just a few POLE tests. So, we have to look at this and that's I think why our healthcare reimbursement came through that if you look at a population level, it is cheaper, and we'll do an extensive cost analysis in PORTEC-4 just to show this. Shannon Westin: That is such a good point. I love that and all of the downstream issues that happen potentially with radiotherapy or with chemotherapy, that's really brilliant. And I'm going to take that back, I love these podcasts. I always learn stuff that I immediately start to use. So, I guess then the last question is, what's next for this particular research and how might we validate what you found? Nanda Horeweg: Yes. Well, as mentioned earlier, for POLE, we have already put the next step in place. So, PORTEC-4a has completed accrual almost two years ago, and we're very much looking forward to do the final analysis within one to one and a half years. So, that will be one of the important next step. And of course, the POLE-BLUE trial is open at the moment, and within a couple of years, we also hope to learn more about this group. So, that's very exciting. Then for the mismatch repair deficient group, while we did not find any particular sensitivity for radiotherapy, and I also don't think that we will conduct another large randomized radiotherapy trial in this group — I think the results that we've observed in the metastasized setting, were really impressive results with immunotherapy are the way forward for this molecular class. And I think the next thing we should do now is prove whether this works or not in the adjuvant setting. And if that's starting with the high-risk patients, which is something we are currently doing in the MMRd-GREEN trial, which is ongoing in the Netherlands, and soon, will open internationally. And from there on, we can work forward if we see that also in this setting the immunotherapy works well. Shannon Westin: And I think GY020 also — NCI trial is also looking at the addition of immunotherapy to radiotherapy in that irony at risk. Carien Creutzberg: Absolutely. Nanda Horeweg: Yeah. And the KEYNOTE-B21 as well — oh, well, already complete accrue. Shannon Westin: The B21, yeah. So, I think those are good. Yeah, that's a really good point for that MMRd group that the immunotherapy really is the way to go, and then more work to be done with the no specific molecular profile. Nanda Horeweg: The NSMP, I think like for the early-stage group, it's quite clear that vaginal brachytherapy is a therapy of choice. But you can of course, try to identify those at such a low risk that you could deescalate treatment. And that's of course what's being done in the Taper trial and also in part, investigated in the PORTEC-4a trial. Carien Creutzberg: And those with higher risk NSMP that we are revisiting hormonal treatments because 90% are estrogen receptor positive, and they have a clearly better prognosis than those with estrogen receptor negative tumors. So, those with estrogen receptor positive tumors can in RAINBO-ORANGE, which will be run led by the UK group, see if we can improve quality of life with less intensive adjuvant treatment. And then you came to the p53 group, that's a good one to stop with. Nanda Horeweg: Yeah, we have very good indications that radiotherapy and chemotherapy is working well for this group. And this is also in line with the guidelines that have been issued in the last few years by many societies. So, I don't think we should change this base of the treatment consisting of radiotherapy and chemotherapy. But since the prognosis is still rather poor, we need to add systemic agents to reduce the risk of metastasis. And preferably, this should be like well-designed based on a proper biological underpinning, plus something that's not too toxic since we're combining the three therapies together. So, this is what we try to do in the RAINBO-RED trial where we will investigate the addition of a PARP inhibitor to chemoradiation in the p53 group. Shannon Westin: Oh, I love that. That's been my whole career, is adding PARP inhibitors wherever I can. Carien Creutzberg): We might also want to mention the HER2 inhibitors, which are also in about 20% of the p53 group has HER2 overexpression. And there is a trial being set up in NCI with trastuzumab and pertuzumab. Shannon Westin: My only concern with that one is I think that the antibody drug conjugates are so much more powerful, the TDX data that we just saw from DESTINY is so impressive. And so, I do wonder, like if we need to move on from kind of some of the older HER2, and get with the program and use some of these more powerful drugs. But with that, I just want to thank Dr. Creutzberg and Horeweg. This was such a great discussion, and obviously, near and dear to my heart talking about endometrial cancer, but I hope our audience enjoyed as well. Just as a reminder, this was a discussion on molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early stage endometroid endometrial cancer, published in the JCO on 9.20.23. I am your host, Shannon Westin, and I hope you'll check out more JCO After Hours wherever you get your podcasts. Have an awesome day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

Carien en ek gesels aan die einde van ‘n besige week :)

Carien van Boxtel's appearance on the podcast last week was a delightful insight into her incredible eye for naturalising, and she turns that eye this week to woodlands.Joining Sarah once again, she shares her 12 top varieties to naturalise any woodland area, whether you're longing to walk through aromatic pastures or colourful bursts of productive flower families.In this episode, discover:Carien's top tips for productive, prolific and pretty bulbs dotted through woodland in the most charming and natural wayThe flower families to pick for unbeatable aroma, like the gorgeously natural native BluebellVarieties to plant for more striking colour and structure, like the brilliantly vigourous Dog's Tooth VioletGet in touch: info@sarahraven.comShop on the Sarah Raven Website: http://bit.ly/3jvbaeuFollow Sarah: https://bit.ly/3jDTvBp

Bringing the haphazard beauty of nature into your own space is a charming prospect, and Carien van Boxtel has an incredible eye for naturalising grassland.This week on ‘grow, cook, eat, arrange' Carien joins Sarah to share her 12 top bulbs for year-round naturalising - with plenty of bonus varieties along the way - and her three essential tips for perfect planting.In this episode, discover:What makes Snowdrops Carien's ‘desert island' flower family for naturalising grassThe later flowering, self-seeding perennial joys of NarcissusCarien's critical tips for planting into meadows and grassland, giving you a bustling, colourful spaceGet in touch: info@sarahraven.comShop on the Sarah Raven Website: http://bit.ly/3jvbaeuFollow Sarah: https://bit.ly/3jDTvBp

Today on Sense of Soul Podcast we have Carien. She joining us today to share an important message, that your life and awareness are one.  Carien helps seekers find their true sense of soul and liberation. She does this with a lot of love, patience, clarity and humor. Just sitting in the energy of Carien alone awakens that non-personal clarity and love that is already within us all. With humour and the sharpest responses. She is not afraid to talk about the most difficult subjects for the mind. Attending Carien's Satsang, your mind will come to the surface. That's exactly what a true seeker is searching for. A true seeker has had enough of their own stories and will experience Carien as a breath of fresh air. Controversial and with a no-nonsense mentality. By many she is called the “head-hunter”, this white lion will see right through you. So you gradually discover what is real, and what is not. Carien facilitates weekly Satsang sessions, a moment of reflection and connection. To come home to yourself and give nourishment to the soul. During these sessions, you are invited to ask questions that you feel or experience at that moment in your life. Once you have had a hint of your true self, there is no going back. Check out the Carien Foundation, go to https://carien.org for the upcoming Satsangs and retreats both online and live. Follow her journey on YouTube, Facebook  and Instagram. Learn more about Sense of Soul Podcast: https://www.senseofsoulpodcast.com Check out the NEW affiliate deals! https://www.mysenseofsoul.com/sense-of-soul-affiliates-page Check out the Ethereal Network! https://www.mysenseofsoul.com/ethereal-network Follow Sense of Soul on Patreon, and join to get ad free episodes, circles, mini series and more! https://www.patreon.com/

Carien en ek praat oor alles en nog wat op ‘n snaakse dag

Willem van Oranje reisde vanaf jonge leeftijd heel Europa door. Een welgestelde Duitse jongen van adel in de zestiende eeuw, die hoge ogen gooide bij zijn oom keizer Karel V, en in Brussel werd opgevoed. René van Stipriaan schreef al een goed ontvangen biografie over het leven van Willem de Zwijger en volgt in zijn nieuwe boek de reizen die van Oranje maakte. Het boek voert langs expedities, pendeltrajecten tussen de paleizen, vluchtroutes en triomftochten. Hoe zag de wereld van Willem van Oranje eruit? Lara Billie Rense spreekt in Wat blijft met biograaf René van Stipriaan over vader des vaderlands Willem van Oranje.  Verder in Wat blijft: fotograaf Erwin Olaf met curator Wim van Sinderen, Carien van der Laan, en een Wat blijft-lijn over Djoke de Jong door Habtamu de Hoop. In het tweede uur van Wat blijft volgt Lotje IJzermans het spoor terug van Wim Kayzer: Met zijn kenmerkende ooglapje en grote bos grijs haar was Wim Kayzer een opvallende verschijning op televisie. In series als Nauwgezet en Wanhopig, Een Schitterend Ongeluk en Van de schoonheid en de troost onderzocht hij de grote vragen van het menszijn. Wie zijn we, wat inspireert ons, waarom doen we wat we doen? Kayzer was gefascineerd door de Tweede Wereldoorlog. In zijn latere leven legde hij zich steeds meer toe op het schrijven. En hij had een heel andere kant, die bijna niemand kende: de familieman die _altijd op zijn hoede- survivalde in Frankrijk. Lotje IJzermans volgt het spoor terug met cameraman Erik van Empel en geluidsman Menno Euwe, uitgever en goede vriend Jan Geurt Gaarlandt, en met dochter Eva Effenberger.  --- Redactie: Laura Iwuchukwu, Nina Ramkisoen, Geerte Verduijn, Maartje Willems Eindredactie: Bram Vollaers

Carien en Ek vang op!

Carien en ek gesels met Elsie!

Carien en ek gesels lekker

Stefan, Carien en Ek gesels boeke

Carien en ek gesels oor luisteraars briefies?

Carien en David gesels oor 'n here reeks interessante goed!

Lekker lag en gesels Stefan, Carien en Ek

In this episode we ‘get into it' with Boulevard Magazine's very own Carien Wessels. After her house in South Africa was struck by lightning and burned to the ground, like a Phoenix, Carien rose from the ashes and built a new life for herself and her boys. Listen to her story of resiliency, courage, love and empowerment. Carien mesmerized us with her accent, kept us on the edge of our seats, and left us with some pretty awesome parenting tips too.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Carien Creutzberg, Nanda Horeweg, and Alexandra Leary to discuss the RAINBO trials. Carien Creutzberg is Professor of Radiation Oncology at Leiden University Medical Center, the Netherlands. She specializes in research and treatment of gynecological cancers and has been the initiator and principal investigator of the four PORTEC trials and the TransPORTEC consortium. She is current chair of the GCIG Endometrial Cancer Committee and past Council member of ESGO and IGCS. Nanda Horeweg is senior researcher at the department of Radiation Oncology of Leiden University Medical Center, the Netherlands. She is one of the principal investigators of the PORTEC team and the international coordinator of the RAINBO program of clinical trials. Alexandra Leary, MD, PhD, is a medical oncologist specializing in gynecological cancers at Gustave Roussy Cancer Center in France. She is the CI for the RAINBO-RED trial and member of the TransPORTEC Consortium. She is current chair of the GCIG Phase II committee, gyne track chair for ESMO Asia, and past gyne track chair for ESMO.    Highlights: - The RAINBO program includes 4 international clinical trials of molecular class-directed novel adjuvant targeted treatment strategies for women with high-risk endometrial cancer. - Women with completely resected invasive stage IA-III endometrial cancer may participate in the RAINBO trial that matches with the molecular class of their tumor. - RAINBO aims to either increase cure rates through the addition of novel targeted therapies or safely reduce toxicity and improve quality of life through treatment de-escalation. - Uniform data collection and central biobanking will enable overarching and translational RAINBO research projects.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Carien Creutzberg, Nanda Horeweg, and Alexandra Leary to discuss the RAINBO trials. Carien Creutzberg is Professor of Radiation Oncology at Leiden University Medical Center, the Netherlands. She specializes in research and treatment of gynecological cancers and has been the initiator and principal investigator of the four PORTEC trials and the TransPORTEC consortium. She is current chair of the GCIG Endometrial Cancer Committee and past Council member of ESGO and IGCS. Nanda Horeweg is senior researcher at the department of Radiation Oncology of Leiden University Medical Center, the Netherlands. She is one of the principal investigators of the PORTEC team and the international coordinator of the RAINBO program of clinical trials. Alexandra Leary, MD, PhD, is a medical oncologist specializing in gynecological cancers at Gustave Roussy Cancer Center in France. She is the CI for the RAINBO-RED trial and member of the TransPORTEC Consortium. She is current chair of the GCIG Phase II committee, gyne track chair for ESMO Asia, and past gyne track chair for ESMO.

In this episode, Susan and Carien discuss:Listening to the Soul's CallingThe Mind and HappinessThe Immensity of SilenceSinging as a way of expressing of the Soul Key Takeaways: Recognize the vital role of self-discovery and letting go during spiritual awakening. Learn about the Carien Foundation's mission to cultivate safe spaces for meaningful connections. Embrace your authentic self and realize the potential of trusting consciousness for abundance. Delve into the world of music and singing as a way to express your soul. Grasp the essence of simplicity and living in the present for everlasting inner tranquility. “The true source of all us all here is silence. It's the immensity of silence.” - Carien Hoekman Connect with Carien:Website: https://carien.org/YouTube: https://www.youtube.com/channel/UCCiK21IWzhXP1dTmCrNKdHQLinked In: https://www.linkedin.com/in/carien-hoekman-29845a61/Facebook: https://www.facebook.com/www.carien.org/Instagram:https://www.instagram.com/thecarienfoundation/ Connect with Susan Kennard:Awaken the Light Within FREE VIDEO COURSETwitter: @susankennardFacebook: Susan Kennard - Expand Your Consciousness, Sparkle to SuccessWebsite: SusanKennard.co.ukLinkedIn: Susan KennardEmail: Susan@SusanKennard.co.ukIf you would like Susan to speak at your event or group, please contact susan@susankennard.co.ukReach out to find the program for you!  Audio production by Turnkey Podcast Productions. You're the expert. Your podcast will prove it.

Carien, Stefan en Ek kuier

Carien gesels lekker met Tilla en Nico!

Margaret catches up with Carien Borst, an artist who lives and works in the Netherlands. She chats about how she struggled with creating a business while maintaining her art's authenticity.  A flow state (being in the moment and creating freely, forgetting everything around you) was hard to achieve during this period. Carien explains that art is like a muscle you can train. You can create conditions that may help pave the way for a flow state . For instance, you can take time, go to a studio, read a book, go outdoors, do research, find things that attract you, but equally, you cannot predict a flow state. Join Margaret and Carien whilst they further explore what their individual art means to them and how they use it during the difficult periods we all experience from time to time.  It is interesting to hear them bounce ideas and you will leave feeling inspired to get creative.Carien Borst https://www.instagram.com/carien_borst/

Carien en Ek gesels Sommer

Carien kuier nog lekker en pas Fred op

Carien vlieg solo

Carien en ek gesels so lekker op ‘n Saterdagmiddag

Kuier saam met my en Carien

Carien, Ek, Natashe, Marelise en Stoffel gesels

Carien en Ek vries so ‘n bietjie

Lekker ‘musings'

Ek en Carien gesels en Carien soek haar bril

Carien en Ek gesels oor ‘n snaakse hartseer week

Carien gesels met die SA span

Luister om te hoor wat Carien gedoen het!

Updates in general - THE STORM PRINCESS AND THE RAVEN KING  is done except for the epilogues! which I'm really enjoying writing because they're great touch-backs to the original Twelve Kingdoms trilogy. And other stuff...The audiobook of GREY MAGIC is here (https://www.audible.com/pd/Grey-Magic-Audiobook/B09Z77GHDL?source_code=AUDFPWS0223189MWT-BK-ACX0-307001&ref=acx_bty_BK_ACX0_307001_rh_us), BRIGHT FAMILIAR is here (https://www.audible.com/pd/Bright-Familiar-Audiobook/B09WSGFLXW?source_code=AUDFPWS0223189MWT-BK-ACX0-303113&ref=acx_bty_BK_ACX0_303113_rh_us) and DARK WIZARD is here (https://www.audible.com/pd/Dark-Wizard-Audiobook/B09QQRHTYZ?source_code=AUDFPWS0223189MWT-BK-ACX0-294201&ref=acx_bty_BK_ACX0_294201_rh_us).The Sorcerous Moons series - now in KU! - is available here (https://www.amazon.com/dp/B09YVVB82N).The form to preorder books for Apollycon is here (https://docs.google.com/forms/d/e/1FAIpQLScbs-nwq5cfOpk-5xzhz1mfUMycvaZ-bRdvmF0uN7--Ii9ioQ/viewform?vc=0&c=0&w=1&flr=0).If you want to support me and the podcast, click on the little heart or follow this link (https://www.paypal.com/paypalme/jeffekennedy).You can watch this podcast on YouTube here https://youtu.be/mESrGsFOnFASign up for my newsletter here! (https://landing.mailerlite.com/webforms/landing/r2y4b9)Support the show